The ELEVATE study was the first multicenter, double-blind, randomized, placebo-controlled, phase 3 trial to evaluate the efficacy of a TPO-RA, eltrombopag 75 mg for 14 days, in increasing the platelet count and reducing the need for platelet transfusions in CLD patients with thrombocytopenia planned to undergo an elective invasive procedure [13]. The gene discussed is TPO; the disease is congenital secretory chloride diarrhea 1.